Dr. Garmezy on the evolving treatment paradigm for progressive urothelial malignancies

“There has been a ton of activity in recent years with new FDA approvals,” says Benjamin Garmezy, MD.

In this video, Benjamin Garmezy, MD, discusses the expanding armamentarium for the treatment of patients with progressive urothelial malignancies. Garmezy is assistant director of Genitourinary Research at Sarah Cannon Research Institute at Tennessee Oncology.